Differentiating multiple system atrophy from parkinson's disease: Contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging

Journal of Neurology Neurosurgery and Psychiatry

Volumn 73, Issue 5, 2002, Pages 517-523

  Ghaemi, M ^a   Hilker, R ^a   Rudolf, J ^a   Sobesky, J ^a   Heiss, W D ^a,b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; DOPAMINE 2 RECEPTOR; FLUORODEOXYGLUCOSE F 18; GLUCOSE; LEVODOPA; RACLOPRIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; FEMALE; GLUCOSE METABOLISM; HUMAN; MALE; MESENCEPHALON; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SHY DRAGER SYNDROME; THREE DIMENSIONAL IMAGING; VOLUMETRY;

ATROPHY; CORPUS STRIATUM; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MESENCEPHALON; MIDDLE AGED; PARKINSON DISEASE; PUTAMEN; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036829477     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.73.5.517     Document Type: Article

References (50)

1. Jankovic J. Parkinsonism-plus syndromes. Mov Disord 1989;4 (suppl 1):95-119.
2. Wenning GK, Tison F, Ben-Shlomo Y, et al. Multiple system atrophy: A review of 203 pathologically proven cases. Mov Disord 1997;12:133-47.
3. Adams RD, Van Bogaert L, Van der Eecken H. Striatonigral degeneration. J Neuropathol Exp Neurol 1964;23:584-608.
4. Andrews JM, Terry RD, Spataro J. Striatonigral degeneration. Clinico-pathological correlations and response to stereotaxic surgery. Arch Neural 1970;23:319-29.
5. Quinn N. Multiple system atrophy - The nature of the beast. J Neural Neurosurg Psychiatry 1989;52 (suppl):78-89.
6. Hughes AJ, Colosimo C, Kleedorfer B, et al. The dopaminergic response in multiple system atrophy. J Neural Neurosurg Psychiatry 1992;55:1009-13.
7. Colosimo C, Albanese A, Hughes AJ, et al. Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease. Arch Neural 1995;52:294-8.
8. Ito H, Kusaka H, Matsumoto S, et al. Striatal efferent involvement and its correlation to levodopa efficacy in patients with multiple system atrophy. Neurology 1996;47:1291-9.
9. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neural 1990;28:547-55.
10. 2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neural 1992;31:184-92.
11. Antonini A, Leenders KL, Vontobel P. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997;120:2187-95.
12. Schulz JB, Skalej M, Wedekind D, et al. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neural 1999;45:65-74.
13. Oppenheimer D. Neuropathology of progressive autonomic failure. In: Bannister R, ed. Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System. Oxford: Oxford University Press, 1983:267-83.
14. Gray F. The neuropathology of Parkinson syndrome. Rev Neurol 1988;144:229-48.
15. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's diesease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
16. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology 1967;17:427-42.
17. Fahn S, Elton RL and the Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, et al, eds. Recent Developments in Parkinson's Disease. Vol 2. New York, NY: MacMillan, 1987:153-63.
18. Gilman S, Low P, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res 1998;8:359-62.
19. Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 1983;305:137-8.
20. 18F]-2-fluoro-2-deoxy-D-glucose: A critical appraisal of optimization procedures. J Cereb Blood Flow Metab 1985;5:115-25.
21. Hume SP, Myers R, Bloomfield PM, et al. Quantification of 11C-labeled raclopride in rat striatum using positron emission tomography. Synapse 1992;12:47-54.
22. Wienhard K, Ericsson L, Grootoonk S, et al. Performance evaluation of the positron scanner ECAT EXACT. J Comput Assist Tomogr 1992;16:804-13.
23. Wienhard K, Dahlbom M, Eriksson L. The ECAT EXACT HR: Performance of a new high resolution positron scanner. J Comput Assist Tomogr 1994;18:110-18.
24. Pietrzyk U, Herholz K, Fink GR, et al. An interactive technique for three-dimensional image registration: Validation for PET, SPECT, MRI and CT brain studies. J Nucl Med 1994;35:2011-18.
25. Stockhausen HM, Pietrzyk U, Herholz K, et al. A method for surface-based quantification of functional data from the human cortex. In: Carson E, Daube-Witherspoon ME, Herscovitch P, eds. Quantification Functional Brain Imaging with Positron Emsission Tomography. San Diego: Academic Press, 1998:139-42.
26. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985;5:584-90.
27. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic topography of Parkinsonism. J Cereb Blood Flow Metab 1994;14:783-801.
28. 2-receptors. Neurology 1994;44:1325-9.
29. 11C]N-Methylspiperone. J Nucl Med 2000;41:65-70.
30. Schrag A, Kingsley D, Phatouros C, et al. Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol Neurosurg Psychiatry 1998;65:65-71.
31. Gilman S, Koeppe RA, Junk L, et al. Patterns of cerebral glucose metabolism detected with positron emission tomography differ in multiple system atrophy and olivopontocerebellar atrophy. Ann Neurol 1994;36:166-75.
32. Kume A, Takahashi A, Hashizume Y, et al. A histometrical and comparative study on Purkinje cell loss and olivary nucleus cell loss in multiple system atrophy. J Neurol Sci 1991;101:178-86.
33. 18F]fluorodeoxyglucose in multiple system atrophy and pure autonomic failure. Clin Auton Res 1991;1:27-36.
34. De Voider AG, Francart J, Laterrre C, et al. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration. Ann Neurol 1989;26:239-47.
35. Churchyard A, Donnan GA, Hughes A. Dopa resistance in multiple system atrophy: Loss of postsynaptic D2 receptors. Ann Neurol 1993;34:219-26.
36. Schocke MFH, Seppi K, Esterhammer R, et al. Diffusion-weighted MRI differentiates the parkinson variant of multipe system atrophy from PD. Neurology 2002;58:575-80.
37. Piccini P, de Yebenz J, Lees AJ, et al. Detection of subclinical cases using 18F-Dopa and 18Fluorodeoxyglucose positron emission tomography. Arch Neurol 2001;58:1846-51.
38. Karbe H, Grond M, Huber M, et al. Subcortical damage and critical dysfunction in progressive supranuclear palsy demonstrated by positron emission tomography. J Neurol 1992;239:98-102.
39. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. Arch Neurol 1964;10:333-59.
40. Steele JC. Progressive supranuclear palsy. Brain 1972;95:693-704.
41. Fearnley JM, Lees AJ. Striatonigral degeneration: A clinicopathological study. Brain 1990;113:1823-42.
42. Castro ME, Pascual J, Romon T, et al. 5-HT1B receptor binding in degenerative movement disorders. Brain Res 1998;790:323-8.
43. 18F]dopa-PET study. Brain 1999;122:1637-50.
44. Wuerker M, Ghaemi M, Bauer A, et al. Changes of midbrain 18 dopa upake in different stages of Parkinson's disease. Mov Disord 1998;13 (suppl 2):42.
45. Ghaemi M, Rudolf J, Hilker R, et al. Increased pineal Fdopa uptake is related to severity of Parkinson's disease - A PET study. J Pineal Res 2001;30:213-19.
46. 18F]fluoro-L-3,4-dihydroxy-phenylalanine in the primate. J Neurochem 1987;48:1077-82.
47. Tison F, Normand E, Jaber M, et al. Aromatic L-amino-acid-decarboxylase (DOPA decarboxylase) gene expression in dopaminergic and serotoninergic cells of the rat brainstem. Neurosci Lett 1991;127:203-6.
48. Brown WD, Taylor MD, Roberts AD, et al. FluoroDOPA-PET shows the non-dopaminergic as well as dopaminergic destinations of levodopa. Neurology 1999;53:1212-18.
49. 18F-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;66:754-8.
50. Asato R, Akiguchi I, Masunaga S, et al. Magnetic resonance imaging distinguishes progressive supranuclear palsy from multiple system atrophy. J Neural Transm 2000;107:1427-36.